- Home
- ACHL vs SCYX Comparison
ACHL vs SCYX Comparison
Compare ACHL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- SCYX
- Stock Information
- Founded
- ACHL 2016
- SCYX 1999
- Country
- ACHL United Kingdom
- SCYX United States
- Employees
- ACHL N/A
- SCYX N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- ACHL Health Care
- SCYX Health Care
- Exchange
- ACHL Nasdaq
- SCYX Nasdaq
- Market Cap
- ACHL 43.6M
- SCYX 50.3M
- IPO Year
- ACHL 2021
- SCYX 2014
- Fundamental
- Price
- ACHL $0.95
- SCYX $1.01
- Analyst Decision
- ACHL Buy
- SCYX Buy
- Analyst Count
- ACHL 2
- SCYX 1
- Target Price
- ACHL $4.00
- SCYX N/A
- AVG Volume (30 Days)
- ACHL 107.8K
- SCYX 194.2K
- Earning Date
- ACHL 11-14-2024
- SCYX 11-06-2024
- Dividend Yield
- ACHL N/A
- SCYX N/A
- EPS Growth
- ACHL N/A
- SCYX N/A
- EPS
- ACHL N/A
- SCYX N/A
- Revenue
- ACHL N/A
- SCYX $8,566,000.00
- Revenue This Year
- ACHL N/A
- SCYX N/A
- Revenue Next Year
- ACHL N/A
- SCYX $405.82
- P/E Ratio
- ACHL N/A
- SCYX N/A
- Revenue Growth
- ACHL N/A
- SCYX N/A
- 52 Week Low
- ACHL $0.63
- SCYX $0.98
- 52 Week High
- ACHL $1.76
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- ACHL 29.24
- SCYX 30.15
- Support Level
- ACHL $0.97
- SCYX $1.11
- Resistance Level
- ACHL $1.01
- SCYX $1.25
- Average True Range (ATR)
- ACHL 0.03
- SCYX 0.08
- MACD
- ACHL -0.01
- SCYX -0.02
- Stochastic Oscillator
- ACHL 0.87
- SCYX 9.26
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.